Home NDC 73362-101 Yorvipath
Product NDC 73362-101
11-digit product format 733620101
Labeler code 73362
Product ID 73362-101_eb81bad9-a369-4eeb-a69e-6920924381b9
Type HUMAN PRESCRIPTION DRUG
Nonproprietary name Palopegteriparatide
Dosage form INJECTION, SOLUTION
Route SUBCUTANEOUS
Labeler Ascendis Pharma, Endocrinology, Inc.
Application NDA216490
Marketing category NDA
Marketing start 2024-08-09
Substance PALOPEGTERIPARATIDE
Active strength 294 ug/.98mL
Pharmacologic classes Parathyroid Hormone Analog [EPC], Parathyroid Hormone [CS]
NDC exclude flag No
Listing certified through 2027-12-31
Current FDA listing Yes Source provenance: Browse the complete Orange Book source catalog · source snapshot 42 .
Orange Book products# Current product rows page 1 of 1 · 3 matching rows.
Application-product, Trade name, Ingredient table Application-product Trade name Ingredient Strength Dosage form / route TE codes RLD / RS Approval date N216490-001 YORVIPATH PALOPEGTERIPARATIDE EQ 0.168MG TERIPARATIDE/0.56ML (EQ 0.168MG TERIPARATIDE/0.56ML) SOLUTION / SUBCUTANEOUS RLD, RS 2024-08-09 N216490-002 YORVIPATH PALOPEGTERIPARATIDE EQ 0.294MG TERIPARATIDE/0.98ML (EQ 0.294MG TERIPARATIDE/0.98ML) SOLUTION / SUBCUTANEOUS RLD, RS 2024-08-09 N216490-003 YORVIPATH PALOPEGTERIPARATIDE EQ 0.42MG TERIPARATIDE/1.4ML (EQ 0.3MG TERIPARATIDE/ML) SOLUTION / SUBCUTANEOUS RLD, RS 2024-08-09
Orange Book patents# Current patent rows page 1 of 1 · 27 matching rows.
Application-product, Patent, Expiration table Application-product Patent Expiration Use code Coverage / status Submission date N216490-001 8906847 2031-04-30 U-3982 Drug substance, Drug product 2024-09-05 N216490-001 11590207 2037-09-28 U-3982 2024-09-05 N216490-001 11759504 2037-09-28 Drug product 2024-09-05 N216490-001 11857603 2037-09-28 U-3982 2024-09-05 N216490-001 11890326 2037-09-28 Drug substance, Drug product 2024-09-05 N216490-001 11918628 2037-09-28 Drug substance, Drug product 2024-09-05 N216490-001 12295989 2037-09-28 U-3982 2025-05-29 N216490-001 12453778 2037-09-28 U-3982 2025-11-12 N216490-001 12403182 2042-11-12 U-3982 Drug product 2025-09-05 N216490-002 8906847 2031-04-30 U-3982 Drug substance, Drug product 2024-09-05 N216490-002 11590207 2037-09-28 U-3982 2024-09-05 N216490-002 11759504 2037-09-28 Drug product 2024-09-05 N216490-002 11857603 2037-09-28 U-3982 2024-09-05 N216490-002 11890326 2037-09-28 Drug substance, Drug product 2024-09-05 N216490-002 11918628 2037-09-28 Drug substance, Drug product 2024-09-05 N216490-002 12295989 2037-09-28 U-3982 2025-05-29 N216490-002 12453778 2037-09-28 U-3982 2025-11-12 N216490-002 12403182 2042-11-12 U-3982 Drug product 2025-09-05 N216490-003 8906847 2031-04-30 U-3982 Drug substance, Drug product 2024-09-05 N216490-003 11590207 2037-09-28 U-3982 2024-09-05 N216490-003 11759504 2037-09-28 Drug product 2024-09-05 N216490-003 11857603 2037-09-28 U-3982 2024-09-05 N216490-003 11890326 2037-09-28 Drug substance, Drug product 2024-09-05 N216490-003 11918628 2037-09-28 Drug substance, Drug product 2024-09-05 N216490-003 12295989 2037-09-28 U-3982 2025-05-29 N216490-003 12453778 2037-09-28 U-3982 2025-11-12 N216490-003 12403182 2042-11-12 U-3982 Drug product 2025-09-05
Orange Book exclusivity# Current exclusivity rows page 1 of 1 · 6 matching rows.
Observed Orange Book product history# Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
Captured, Edition, Application-product table Captured Edition Application-product Trade name Strength Dosage form / route Product TE source text RLD / RS Approval date Source SHA-256 2026-08-18 06:07:40 2026-07 N216490-001 YORVIPATH EQ 0.168MG TERIPARATIDE/0.56ML (EQ 0.168MG TERIPARATIDE/0.56ML) SOLUTION / SUBCUTANEOUS RLD, RS 2024-08-09 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N216490-002 YORVIPATH EQ 0.294MG TERIPARATIDE/0.98ML (EQ 0.294MG TERIPARATIDE/0.98ML) SOLUTION / SUBCUTANEOUS RLD, RS 2024-08-09 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N216490-003 YORVIPATH EQ 0.42MG TERIPARATIDE/1.4ML (EQ 0.3MG TERIPARATIDE/ML) SOLUTION / SUBCUTANEOUS RLD, RS 2024-08-09 caaa826d4ba7…2026-02-19 14:30 UTC 2026-02 N216490-001 YORVIPATH EQ 0.168MG TERIPARATIDE/0.56ML (EQ 0.168MG TERIPARATIDE/0.56ML) SOLUTION / SUBCUTANEOUS RLD, RS 2024-08-09 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N216490-002 YORVIPATH EQ 0.294MG TERIPARATIDE/0.98ML (EQ 0.294MG TERIPARATIDE/0.98ML) SOLUTION / SUBCUTANEOUS RLD 2024-08-09 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N216490-003 YORVIPATH EQ 0.42MG TERIPARATIDE/1.4ML (EQ 0.3MG TERIPARATIDE/ML) SOLUTION / SUBCUTANEOUS RLD 2024-08-09 011fe1cb6892…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N216490-001 YORVIPATH EQ 0.168MG TERIPARATIDE/0.56ML (EQ 0.168MG TERIPARATIDE/0.56ML) SOLUTION / SUBCUTANEOUS RLD, RS 2024-08-09 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N216490-002 YORVIPATH EQ 0.294MG TERIPARATIDE/0.98ML (EQ 0.294MG TERIPARATIDE/0.98ML) SOLUTION / SUBCUTANEOUS RLD 2024-08-09 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N216490-003 YORVIPATH EQ 0.42MG TERIPARATIDE/1.4ML (EQ 0.3MG TERIPARATIDE/ML) SOLUTION / SUBCUTANEOUS RLD 2024-08-09 31067a03dcf5…2025-08-23 18:47 UTC 2025-08 N216490-001 YORVIPATH EQ 0.168MG TERIPARATIDE/0.56ML (EQ 0.168MG TERIPARATIDE/0.56ML) SOLUTION / SUBCUTANEOUS RLD, RS 2024-08-09 6a471c1ec25d…2025-08-23 18:47 UTC 2025-08 N216490-002 YORVIPATH EQ 0.294MG TERIPARATIDE/0.98ML (EQ 0.294MG TERIPARATIDE/0.98ML) SOLUTION / SUBCUTANEOUS RLD 2024-08-09 6a471c1ec25d…2025-08-23 18:47 UTC 2025-08 N216490-003 YORVIPATH EQ 0.42MG TERIPARATIDE/1.4ML (EQ 0.3MG TERIPARATIDE/ML) SOLUTION / SUBCUTANEOUS RLD 2024-08-09 6a471c1ec25d…2025-03-22 03:13 UTC · 3 captures of this ZIP 2025-03 N216490-001 YORVIPATH EQ 0.168MG TERIPARATIDE/0.56ML (EQ 0.168MG TERIPARATIDE/0.56ML) SOLUTION / SUBCUTANEOUS RLD, RS 2024-08-09 fd3edfee7708…2025-03-22 03:13 UTC · 3 captures of this ZIP 2025-03 N216490-002 YORVIPATH EQ 0.294MG TERIPARATIDE/0.98ML (EQ 0.294MG TERIPARATIDE/0.98ML) SOLUTION / SUBCUTANEOUS RLD 2024-08-09 fd3edfee7708…2025-03-22 03:13 UTC · 3 captures of this ZIP 2025-03 N216490-003 YORVIPATH EQ 0.42MG TERIPARATIDE/1.4ML (EQ 0.3MG TERIPARATIDE/ML) SOLUTION / SUBCUTANEOUS RLD 2024-08-09 fd3edfee7708…2025-02-26 10:13 UTC · 3 captures of this ZIP 2025-02 N216490-001 YORVIPATH EQ 0.168MG TERIPARATIDE/0.56ML (EQ 0.168MG TERIPARATIDE/0.56ML) SOLUTION / SUBCUTANEOUS RLD, RS 2024-08-09 b8a1b40f171c…2025-02-26 10:13 UTC · 3 captures of this ZIP 2025-02 N216490-002 YORVIPATH EQ 0.294MG TERIPARATIDE/0.98ML (EQ 0.294MG TERIPARATIDE/0.98ML) SOLUTION / SUBCUTANEOUS RLD 2024-08-09 b8a1b40f171c…2025-02-26 10:13 UTC · 3 captures of this ZIP 2025-02 N216490-003 YORVIPATH EQ 0.42MG TERIPARATIDE/1.4ML (EQ 0.3MG TERIPARATIDE/ML) SOLUTION / SUBCUTANEOUS RLD 2024-08-09 b8a1b40f171c…2025-01-19 17:59 UTC · 7 captures of this ZIP 2025-01 N216490-001 YORVIPATH EQ 0.168MG TERIPARATIDE/0.56ML (EQ 0.168MG TERIPARATIDE/0.56ML) SOLUTION / SUBCUTANEOUS RLD, RS 2024-08-09 03ed91905a0d…2025-01-19 17:59 UTC · 7 captures of this ZIP 2025-01 N216490-002 YORVIPATH EQ 0.294MG TERIPARATIDE/0.98ML (EQ 0.294MG TERIPARATIDE/0.98ML) SOLUTION / SUBCUTANEOUS RLD 2024-08-09 03ed91905a0d…2025-01-19 17:59 UTC · 7 captures of this ZIP 2025-01 N216490-003 YORVIPATH EQ 0.42MG TERIPARATIDE/1.4ML (EQ 0.3MG TERIPARATIDE/ML) SOLUTION / SUBCUTANEOUS RLD 2024-08-09 03ed91905a0d…2024-12-13 21:23 UTC · 2 captures of this ZIP 2024-12 N216490-001 YORVIPATH EQ 0.168MG TERIPARATIDE/0.56ML (EQ 0.168MG TERIPARATIDE/0.56ML) SOLUTION / SUBCUTANEOUS RLD, RS 2024-08-09 2680178bc6a6…2024-12-13 21:23 UTC · 2 captures of this ZIP 2024-12 N216490-002 YORVIPATH EQ 0.294MG TERIPARATIDE/0.98ML (EQ 0.294MG TERIPARATIDE/0.98ML) SOLUTION / SUBCUTANEOUS RLD 2024-08-09 2680178bc6a6…2024-12-13 21:23 UTC · 2 captures of this ZIP 2024-12 N216490-003 YORVIPATH EQ 0.42MG TERIPARATIDE/1.4ML (EQ 0.3MG TERIPARATIDE/ML) SOLUTION / SUBCUTANEOUS RLD 2024-08-09 2680178bc6a6…2024-09-14 05:58 UTC · 2 captures of this ZIP 2024-09 N216490-001 YORVIPATH EQ 0.168MG TERIPARATIDE/0.56ML (EQ 0.168MG TERIPARATIDE/0.56ML) SOLUTION / SUBCUTANEOUS RLD, RS 2024-08-09 5bbf6a4d5a75…2024-09-14 05:58 UTC · 2 captures of this ZIP 2024-09 N216490-002 YORVIPATH EQ 0.294MG TERIPARATIDE/0.98ML (EQ 0.294MG TERIPARATIDE/0.98ML) SOLUTION / SUBCUTANEOUS RLD 2024-08-09 5bbf6a4d5a75…2024-09-14 05:58 UTC · 2 captures of this ZIP 2024-09 N216490-003 YORVIPATH EQ 0.42MG TERIPARATIDE/1.4ML (EQ 0.3MG TERIPARATIDE/ML) SOLUTION / SUBCUTANEOUS RLD 2024-08-09 5bbf6a4d5a75…2024-11-08 22:44 UTC · 3 captures of this ZIP 2024-11 N216490-001 YORVIPATH EQ 0.168MG TERIPARATIDE/0.56ML (EQ 0.168MG TERIPARATIDE/0.56ML) SOLUTION / SUBCUTANEOUS RLD, RS 2024-08-09 d8e5a09893c0…2024-11-08 22:44 UTC · 3 captures of this ZIP 2024-11 N216490-002 YORVIPATH EQ 0.294MG TERIPARATIDE/0.98ML (EQ 0.294MG TERIPARATIDE/0.98ML) SOLUTION / SUBCUTANEOUS RLD 2024-08-09 d8e5a09893c0…2024-11-08 22:44 UTC · 3 captures of this ZIP 2024-11 N216490-003 YORVIPATH EQ 0.42MG TERIPARATIDE/1.4ML (EQ 0.3MG TERIPARATIDE/ML) SOLUTION / SUBCUTANEOUS RLD 2024-08-09 d8e5a09893c0…2024-10-29 15:01 UTC 2024-10 N216490-001 YORVIPATH EQ 0.168MG TERIPARATIDE/0.56ML (EQ 0.168MG TERIPARATIDE/0.56ML) SOLUTION / SUBCUTANEOUS RLD, RS 2024-08-09 d06236e962d9…2024-10-29 15:01 UTC 2024-10 N216490-002 YORVIPATH EQ 0.294MG TERIPARATIDE/0.98ML (EQ 0.294MG TERIPARATIDE/0.98ML) SOLUTION / SUBCUTANEOUS RLD 2024-08-09 d06236e962d9…2024-10-29 15:01 UTC 2024-10 N216490-003 YORVIPATH EQ 0.42MG TERIPARATIDE/1.4ML (EQ 0.3MG TERIPARATIDE/ML) SOLUTION / SUBCUTANEOUS RLD 2024-08-09 d06236e962d9…2026-07-26 02:55 UTC · 3 captures of this ZIP 2026-06 N216490-001 YORVIPATH EQ 0.168MG TERIPARATIDE/0.56ML (EQ 0.168MG TERIPARATIDE/0.56ML) SOLUTION / SUBCUTANEOUS RLD, RS 2024-08-09 a50c72e98297…2026-07-26 02:55 UTC · 3 captures of this ZIP 2026-06 N216490-002 YORVIPATH EQ 0.294MG TERIPARATIDE/0.98ML (EQ 0.294MG TERIPARATIDE/0.98ML) SOLUTION / SUBCUTANEOUS RLD, RS 2024-08-09 a50c72e98297…2026-07-26 02:55 UTC · 3 captures of this ZIP 2026-06 N216490-003 YORVIPATH EQ 0.42MG TERIPARATIDE/1.4ML (EQ 0.3MG TERIPARATIDE/ML) SOLUTION / SUBCUTANEOUS RLD, RS 2024-08-09 a50c72e98297…
Observed Orange Book patent history# Patent history page 1 of 6 · 237 observed states.
Captured, Edition, Application-product table Captured Edition Application-product Patent Expiration Use code Coverage / status Submission date Source SHA-256 2026-08-18 06:07:40 2026-07 N216490-001 8906847 2031-04-30 U-3982 Drug substance, Drug product 2024-09-05 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N216490-001 11590207 2037-09-28 U-3982 2024-09-05 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N216490-001 11759504 2037-09-28 Drug product 2024-09-05 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N216490-001 11857603 2037-09-28 U-3982 2024-09-05 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N216490-001 11890326 2037-09-28 Drug substance, Drug product 2024-09-05 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N216490-001 11918628 2037-09-28 Drug substance, Drug product 2024-09-05 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N216490-001 12295989 2037-09-28 U-3982 2025-05-29 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N216490-001 12453778 2037-09-28 U-3982 2025-11-12 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N216490-001 12403182 2042-11-12 U-3982 Drug product 2025-09-05 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N216490-002 8906847 2031-04-30 U-3982 Drug substance, Drug product 2024-09-05 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N216490-002 11590207 2037-09-28 U-3982 2024-09-05 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N216490-002 11759504 2037-09-28 Drug product 2024-09-05 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N216490-002 11857603 2037-09-28 U-3982 2024-09-05 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N216490-002 11890326 2037-09-28 Drug substance, Drug product 2024-09-05 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N216490-002 11918628 2037-09-28 Drug substance, Drug product 2024-09-05 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N216490-002 12295989 2037-09-28 U-3982 2025-05-29 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N216490-002 12453778 2037-09-28 U-3982 2025-11-12 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N216490-002 12403182 2042-11-12 U-3982 Drug product 2025-09-05 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N216490-003 8906847 2031-04-30 U-3982 Drug substance, Drug product 2024-09-05 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N216490-003 11590207 2037-09-28 U-3982 2024-09-05 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N216490-003 11759504 2037-09-28 Drug product 2024-09-05 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N216490-003 11857603 2037-09-28 U-3982 2024-09-05 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N216490-003 11890326 2037-09-28 Drug substance, Drug product 2024-09-05 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N216490-003 11918628 2037-09-28 Drug substance, Drug product 2024-09-05 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N216490-003 12295989 2037-09-28 U-3982 2025-05-29 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N216490-003 12453778 2037-09-28 U-3982 2025-11-12 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N216490-003 12403182 2042-11-12 U-3982 Drug product 2025-09-05 caaa826d4ba7…2026-02-19 14:30 UTC 2026-02 N216490-001 8906847 2031-04-30 U-3982 Drug substance, Drug product 2024-09-05 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N216490-001 11590207 2037-09-28 U-3982 2024-09-05 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N216490-001 11759504 2037-09-28 Drug product 2024-09-05 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N216490-001 11857603 2037-09-28 U-3982 2024-09-05 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N216490-001 11890326 2037-09-28 Drug substance, Drug product 2024-09-05 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N216490-001 11918628 2037-09-28 Drug substance, Drug product 2024-09-05 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N216490-001 12295989 2037-09-28 U-3982 2025-05-29 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N216490-001 12453778 2037-09-28 U-3982 2025-11-12 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N216490-001 12403182 2042-11-12 U-3982 Drug product 2025-09-05 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N216490-002 8906847 2031-04-30 U-3982 Drug substance, Drug product 2024-09-05 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N216490-002 11590207 2037-09-28 U-3982 2024-09-05 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N216490-002 11759504 2037-09-28 Drug product 2024-09-05 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N216490-002 11857603 2037-09-28 U-3982 2024-09-05 011fe1cb6892…
Observed Orange Book exclusivity history# Exclusivity history page 1 of 2 · 69 observed states.
Additional Listing Data#
Finished product Yes
Brand name base Yorvipath
Listing expiration 2027-12-31 Active Ingredients# Ingredient, Strength table Ingredient Strength PALOPEGTERIPARATIDE 294 ug/.98mL
Harmonized UNII identifiers# UNII identifiers page 1 of 1 · 1 matching rows.
Identifier, FDA.report destination table Identifier FDA.report destination G2N64C3385 Internal UNII lookup
Harmonized RxCUI identifiers# RxCUI identifiers page 1 of 1 · 6 matching rows.
Identifier, FDA.report destination table Identifier FDA.report destination 2693637 Internal RxNorm lookup 2693643 Internal RxNorm lookup 2693645 Internal RxNorm lookup 2693646 Internal RxNorm lookup 2693647 Internal RxNorm lookup 2693648 Internal RxNorm lookup
Harmonized SPL set identifiers# SPL set identifiers page 1 of 1 · 1 matching rows.
DailyMed Product Concepts# DailyMed Package Descriptions# Package NDC, Product, Description table Package NDC Product Description Form Quantity Strength SPL version 73362-101-01 Yorvipath 2 in 1 CARTON INJECTION, SOLUTION 2 7 73362-101-02 Yorvipath 1 in 1 BOX INJECTION, SOLUTION 1 7 73362-101-03 Yorvipath 0.98 mL in 1 CARTRIDGE INJECTION, SOLUTION 0.98 7 73362-101-03 Yorvipath 1 in 1 SYRINGE INJECTION, SOLUTION 1 7
DailyMed Dashboard NDC Coverage# NDC, Dashboard title, SPL version table NDC Dashboard title SPL version Validation Dashboard ZIP 73362-101 YORVIPATH (PALOPEGTERIPARATIDE) INJECTION, SOLUTION [ASCENDIS PHARMA, ENDOCRINOLOGY, INC.] 4 Current NDC, 4 package rows 20241019_a1fa23fd-c434-443e-9a17-5750578c8602.zip
openFDA label cross-check# OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
Matched openFDA labels page 1 of 1 · 1 matching rows.
Brand, Generic, Manufacturer table Brand Generic Manufacturer SPL set ID Effective date Available safety fields Join Yorvipath PALOPEGTERIPARATIDE Ascendis Pharma, Endocrinology, Inc. a1fa23fd-c434-443e-9a17-5750578c8602 2026-08-12 Warnings, Adverse reactions Exact identifier application applno (NDA): 216490 application number: NDA216490 ndc (product): 73362-101
DailyMed RxNorm Mappings# Packages# Package NDC, 11-digit format, Description table Package NDC 11-digit format Description Units Marketing start Sample Exclude flag Status 73362-101-01 73362010101 2 BOX in 1 CARTON (73362-101-01) / 1 SYRINGE in 1 BOX (73362-101-02) / 1 CARTRIDGE in 1 SYRINGE (73362-101-03) / .98 mL in 1 CARTRIDGE 2 box 2024-08-09 No No Current 73362-101-02 73362010102 1 in 1 BOX Historical 73362-101-03 73362010103 0.98 mL in 1 CARTRIDGE 0.98 ml Historical